MabPlex International
Manufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
4059 Clipper Ct, Fremont, California, 94...Phone Number
(510) 830-1065Website
www.mabplex.comRevenue
$21.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About MabPlex International
MabPlex International Ltd (MabPlex), a leading and fully integrated, global Contract Development and Manufacturing Organization (CDMO), offers an advanced biologics platform and comprehensive and integrated solutions to global (bio-) pharmaceutical developers. Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA) offering high quality services from biologics drug development to commercial manufacturing. MabPlex currently has over 60,000 square meters of R&D and production facilities, a total of 9 monoclonal antibody (mAb) Drug Substance (DS) production lines, 2 Antibody-drug Conjugate (ADC) DS production lines, as well as mAb formulation and ADC formulation lines. The commercial production service is designed to help customers accelerate the progress of clinical trials and support market launch. MabPlex has established a talented team of more than 400 employees provideding Contract Development and ManufacturingRead more
MabPlex International Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MabPlex International your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if MabPlex International is spiking on competitors!
Check if MabPlex International has recently received funding, and reach out quickly before it becomes old news!
MabPlex International, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at MabPlex International
Product Launch: Get notified when MabPlex International launches new products
Click to see if MabPlex International had a recent Job posting/layoffs
Earning: See what the market has to say on MabPlex International recently announced quarterly report
Funding: Get notified immidiatlly once MabPlex International has new funding data
Recommended Actions
Find VP level buyers at MabPlex International
Find 3 more new buyers
Company Profile Activity
Activity Insights
MabPlex International is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MabPlex International is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MabPlex International.
MabPlex International financials insights
Gather financial insights about MabPlex International, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$59.1M
MabPlex International Tech Stack
A closer look at the technologies used by MabPlex International
See more technologies
MabPlex International News & Media
MabPlex Raises $71 Million for Biopharmaceutical CDMO Services
MabPlex International, a biologics CDMO located in Yantai, completed a $71 million Series B financing led by PE firms DT Capital Partners and Huajin Capital. Founded in 2013, MabPlex provides global CDMO services for biopharmaceuticals, including mAbs, recombinant proteins, ADCs and bispecifics. The company offers contract services that range from DNA to finished drug products. Its CHO cell line platform is designed to move candidates quickly through the development process. In early 2019, MabPlChinese biopharma firm MabPlex nets $71m in Series B round
The Series B financing was led by Chinese private equity firms DT Capital Partners and Huajin Capital.MabPlex Launches Two New 2,000-liter Cell Culture Production Lines;...
MabPlex International has launched operations with two new cell culture production lines with GE brand 2,000-liter single-use bioreactors. This expansion demonstrates the company's commitment to... (PRWeb February 25, 2020) Read the full story at https://www.prweb.com/releases/mabplex_launches_two_new_2_000_liter_cell_culture_production_lines_additional_production_lines_planned/prweb16929903.htmMabPlex International Announces Appointment of Dr. Yongjian Wu (Ph.D.)...
MabPlex International Ltd. (MabPlex) has appointed Yongjian Wu, Ph.D as Chief Operating Officer (COO) of MabPlex USA. Dr. Wu is a senior biopharmaceutical professional with over 18 years of Chemistry,... (PRWeb November 18, 2019) Read the full story at https://www.prweb.com/releases/mabplex_international_announces_appointment_of_dr_yongjian_wu_ph_d_as_chief_operating_officer_of_mabplex_usa/prweb16727757.htm
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MabPlex International
Sign Up For FreeTo access detailed company insights
MabPlex International Ltd (MabPlex), a leading and fully integrated, global Contract Development and Manufacturing Organization (CDMO), offers an advanced biologics platform and comprehensive and integrated solutions to global (bio-) pharmaceutical developers. Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one s... Read More
